Viridian Therapeutics, Inc./DE Revenue from Grants (Deprecated 2018-01-31)
Viridian Therapeutics, Inc./DE (VRDN) reported Revenue from Grants (Deprecated 2018-01-31) of $28.00 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromGrants · last filed 2018-05-09
- Viridian Therapeutics, Inc./DE revenue from grants (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $28.00K, a 93.81% decline year-over-year.
- Viridian Therapeutics, Inc./DE revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $86.00K, a 50.57% decline year-over-year.
- Viridian Therapeutics, Inc./DE revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $138.00K, a 37.56% decline year-over-year.
- Viridian Therapeutics, Inc./DE revenue from grants (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $230.00K, a 14.18% decline year-over-year.
- Viridian Therapeutics, Inc./DE revenue from grants (deprecated 2018-01-31) for fiscal 2017 was $906.00K, a 36.65% increase from fiscal 2016.
- Viridian Therapeutics, Inc./DE revenue from grants (deprecated 2018-01-31) for fiscal 2016 was $663.00K.
| Period end | Revenue from Grants (Deprecated 2018-01-31) 3 month | Revenue from Grants (Deprecated 2018-01-31) 6 month | Revenue from Grants (Deprecated 2018-01-31) 9 month | Revenue from Grants (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $28.00K 10-Q · filed 2018-05-09 | $114.00K derived: sum of 2 quarters · filed 2018-05-09 | $252.00K derived: sum of 3 quarters · filed 2018-05-09 | $482.00K derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $86.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $224.00K derived: sum of 2 quarters · filed 2018-03-15 | $454.00K derived: sum of 3 quarters · filed 2018-03-15 | $906.00K 10-K · filed 2018-03-15 |
| 2017-09-30 | $138.00K 10-Q · filed 2017-11-09 | $368.00K derived: sum of 2 quarters · filed 2017-11-09 | $820.00K 10-Q · filed 2017-11-09 | $994.00K derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $230.00K 10-Q · filed 2017-08-11 | $682.00K 10-Q · filed 2017-08-11 | $856.00K derived: sum of 3 quarters · filed 2018-05-09 | $1.08M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $452.00K 10-Q · filed 2018-05-09 | $626.00K derived: sum of 2 quarters · filed 2018-05-09 | $847.00K derived: sum of 3 quarters · filed 2018-05-09 | $1.11M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $395.00K derived: sum of 2 quarters · filed 2018-03-15 | $663.00K derived: sum of 3 quarters · filed 2018-03-15 | $663.00K 10-K · filed 2018-03-15 |
| 2016-09-30 | $221.00K 10-Q · filed 2017-11-09 | $489.00K derived: sum of 2 quarters · filed 2017-11-09 | $489.00K 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $268.00K 10-Q · filed 2017-08-11 | $268.00K 10-Q · filed 2017-08-11 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |